Elizabeth R. Volkmann, MD, MS

Elizabeth R. Volkmann, MD, MS

Primary Location
Westwood Specialty Care
200 Medical Plaza
Suite 365
Los Angeles, California 90095


Dr. Elizabeth Volkmann is the Director of the UCLA Scleroderma Program and the founder and Co-Director of the UCLA Connective Tissue Disease-Related Interstitial Lung Disease (CTD-ILD) Program. She is an internationally recognized expert in systemic sclerosis and connective tissue disease-related interstitial lung disease.

Board-certified in both Internal Medicine and Rheumatology, Dr. Volkmann graduated from Pomona College where she majored in Neuroscience and minored in Dance. She received her medical degree from UCLA David Geffen School of Medicine, and subsequently completed her residency in Internal Medicine and fellowship in Rheumatology at UCLA. During her fellowship, she participated in the Specialty Training and Advanced Research (STAR) Program and earned her Master of Science degree in Clinical Research.

Dr. Volkmann is an active clinical and translational researcher in systemic sclerosis and interstitial lung disease. Her research focuses on developing personalized treatment approaches for patients through the discovery of novel biomarkers. She pioneered the first study to investigate the gut microbiome in patients with systemic sclerosis and now leads an international consortium of investigators dedicated to understanding how the gut microbiome contributes to inflammation and clinical symptoms in patients with systemic sclerosis. She also participates in clinical trials to help identify new therapies for patients with autoimmune diseases.

She strives to provide humanistic and compassionate care and seeks to empower her patients to improve their health through traditional, as well as more holistic approaches.

She enjoys being active in nature (running, hiking, swimming, riding horses), and she loves to travel, dance and spend time with her family and friends.

Patient Stories

Other Links

Other Videos

Note: Website links may expire without notice.




Medical Board Certifications

Rheumatology, American Board of Internal Medicine, 2014
Internal Medicine, American Board of Internal Medicine, 2013


UCLA School of Medicine, 2014


UCLA School of Medicine, 2011


UCLA School of Medicine, 2010


UCLA School of Medicine, MS, 2014
UCLA School of Medicine, MD, 2008


Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center



  • Systemic Sclerosis
  • Interstitial Lung Disease
  • Pulmonary Hypertension
  • Microbiome


Link to Dr. Volkmann's PubMed publications

Selected publications

  1. Volkmann ER, Steen VD, Li N, Roth MD, et al. Racial disparities in systemic sclerosis: Short- and long-term morbidity and mortality outcomes of African American participants of SLS I and II. ACR Open Rheumatology 2020;3:8-16.
  2. Volkmann ER, Hoffmann-Vold A-M, Chang Y-L, et al. Longitudinal characterisation of the gastrointestinal tract microbiome in systemic sclerosis.  EMJ 2020;5:110-8.
  3. Volkmann ER, Tashkin DP, LeClair H, et al. ACR Open Rheumatology 2020;2:362-70.
  4. Volkmann ER, Tashkin DP, Sim M, et al. Early progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Annals of Rheumatic Diseases 2019;78:122-30.
  5. Volkmann ER, Tashkin DP, Kuwana M, et al. Progression of interstitial lung disease in systemic sclerosis: The importance of pneumoproteins KL-6 and CCL-18. Arthritis and Rheumatology 2019;71:2059-67.
  6. Volkmann ER, Varga J. Emerging treatments for systemic sclerosis. Nature Rev Rheumatology 2019;15:208-24.
  7. Volkmann ER, Tashkin DP, Sim M, et al. Cyclophosphamide for systemic sclerosis-related interstitial lung disease: A comparison of Scleroderma Lung Studies I and II. Journal of Rheumatology 2019;46:1316-25.
  8. Volkmann ER, Tashkin DP, Li N, et al. Mycophenolate versus placebo for patients with systemic sclerosis-related interstitial lung disease. Arthritis and Rheumatol 2017;69:1451-60.
  9. Volkmann ER, Hoffmann-Vold A-M, Chang Y-L, et al. The systemic sclerosis disease state is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Gastroenterology 2017;4e000134.
  10. Volkmann ER, Chang Y-L, Barroso N, et al. Association of systemic sclerosis with a unique colonic microbial consortium. Arthritis and Rheumatology 2016;68:1483-92.



  • Top Doctors, Los Angeles Magazine, 2021
  • Southern California Rising Stars, Super Doctors®, 2021
  • Edith Busch-Stiftung Award in Rheumatology, 2020
  • Southern California Rising Stars, Super Doctors®, 2020
  • Southern California Rising Stars, Super Doctors®, 2019